Consultation: Removing zuranolone from the Prescription Drug List
Current status: Open
Opened on February 7, 2026 and will close to new input on April 18, 2026.
This consultation provides an opportunity to comment on the proposal to remove “zuranolone or its salts” from both the Human and Veterinary parts of the Prescription Drug List (PDL).
Join in: How to participate
You may submit comments on this proposed change to control zuranolone under the Controlled Drugs and Substances Act (CDSA) to Health Canada, preferably in electronic format, within 70 days from the date of this notice to:
Email: csd.regulatory.policy-politique.reglementaire.dsc@hc-sc.gc.ca
Should you have any questions about this consultation related to the proposed amendment to the PDL, please contact:
Health Canada
Prescription Drug Status Committee
6th Floor Holland Cross – Tower B
Address locator: 3106C
1600 Scott Street
Ottawa ON K1A 0K9
Email: drug.prescription.status-statut.dordonnance.des.drogues@hc-sc.gc.ca
Who is the focus of this consultation
We will engage with:
- interested members of the public
- healthcare practitioners
- healthcare professional associations
- any other interested stakeholders
Related information
- Canada Gazette Part I
- Prescription Drug List
- Controlled Drugs and Substances Act
- Benzodiazepines and Other Targeted Substances Regulations
- Food and Drugs Act
Contact us
Comments on the proposed change to control zuranolone under the CDSA should be provided to:
Office of Legislative and Regulatory Affairs
Controlled Substances and Overdose Response Directorate
Health Canada
Email: csd.regulatory.policy-politique.reglementaire.dsc@hc-sc.gc.ca